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SUMMARY – Despite prolonged survival and better quality of life as compared to dialysis, 
kidney transplantation frequently presents with a complex set of medical issues that require inten-
sive management to protect graft function. Metabolic acidosis has an impact on several metabolic 
complications such as mineral and muscle metabolism, nutritional status and anemia. It may also 
have an effect on graft function, possibly through the stimulation of adaptive mechanisms aimed at 
maintaining acid-base homeostasis. We investigated current practice in the evaluation of metabolic 
acidosis at one of the largest transplant centers in the Eurotransplant region. Adult renal transplant 
recipients having received allograft from January 2011 to August 2012 were included in the investi-
gation. We recorded the frequency of measuring the parameters of venous blood gas analysis, as well 
as creatinine and urea levels, creatinine clearance, proteinuria, calcium, phosphate and potassium 
blood levels, body mass index and the time spent on dialysis prior to kidney transplantation. Out of 
203 patients who had received renal allograft at our institution during the observed period, 191 (124 
males and 67 females, age range from 18 to 77 years) were enrolled in the study. Of these, only 92 
(48.167%) patients had parameters of venous blood gas analysis measured at some time after kidney 
transplantation. Acid-base status was determined more often in males (77 males vs. 22 females, 
p=0.001). Patients with pH/blood gas analysis performed were found to have significantly higher 
creatinine and urea levels and significantly lower creatinine clearance (p<0.001 both). Serum cal-
cium levels were also significantly lower in this group of patients (p<0.001). Metabolic acidosis is a 
very important clinical issue that needs to be monitored in every transplant recipient. Its effects on 
graft function, nutritional status, anemia and bone mass are complex but can be successfully mana-
ged. Our study showed metabolic acidosis to be linked with significantly higher creatinine and urea 
levels, decreased creatinine clearance and lower calcium levels. Nevertheless, metabolic acidosis still 
stays a highly underestimated problem among nephrologists dealing with transplant recipients. We 
suggest regular determination of the acid-base status in renal transplant recipients.
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Introduction
Kidney transplantation is the treatment of choice 
for patients with end-stage renal disease (ESRD)1. 
Although the quality of life improves significantly 
after transplantation, these patients frequently pres-
ent with a complex set of medical issues that require 
intensive management to protect graft function2,3. 
One of the common but highly underestimated issues 
that can occur after transplantation is the presence of 
metabolic acidosis4. Metabolic acidosis is an inevitable 
complication associated with progressive loss of kidney 
function5. It appears when the glomerular filtration 
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rate (GFR) falls below 25 mL/min/1.73 m2 6. It arises 
from difference between the excretion of hydrogen and 
the synthesis of ammonia ions7-9. Damaged renal tu-
bules cannot contribute to maintaining the acid-base 
balance by reabsorbing the daily filtrated HCO3− and 
synthesizing new HCO3− ions6. Metabolic acidosis is 
usually mild to moderate but can lead to several meta-
bolic complications if not properly controlled6,10. It is 
one of the important causes of protein energy wasting 
(PEW) and may trigger muscle loss in patients with 
chronic kidney disease (CKD)11. Furthermore, it con-
tributes to the development of chronic kidney bone 
disease by increasing bone resorption and inhibiting 
bone formation6,12. A recent study by Mizumoto et al. 
showed that acidic environment could play a very im-
portant role in regulating hepcidin homeostasis, thus 
being one of the factors contributing to the etiology 
of anemia of chronic disease13. It is also known that 
metabolic acidosis can severely affect graft function 
by causing progressive tubulointerstitial injury and a 
decline in GFR5,8,10,14. All these metabolic effects are 
complex but can be successfully managed10. Therefore, 
metabolic acidosis needs to be carefully monitored in 
every transplant recipient.
The aim of this study was to investigate current 
practice in the evaluation of metabolic acidosis at the 
Zagreb University Hospital Center (UHC).
Patients and Methods 
Study design
All adult renal transplant recipients having re-
ceived allograft from January 2011 to August 2012 
were included in the study. Among them, only data on 
the recipients whose renal function remained stable 
for at least 3 months after transplantation were used 
in the analysis. 
Study measurements
Laboratory and clinical data were collected from 
medical records and charts. We recorded the frequen-
cy of measuring parameters of venous blood gas anal-
ysis (acid-base status, ABS), as well as creatinine and 
urea levels, creatinine clearance, proteinuria, calcium, 
phosphate and potassium blood levels, body mass in-
dex, and the time spent on dialysis prior to kidney 
transplantation. 
Statistical analysis 
Statistical evaluation of the data was carried out 
using the SPSS statistical package, version 17.0 for 
Windows. Baseline data were reported using de-
scriptive statistics. Normality of distribution for con-
tinuous variables was analyzed using Kolmogorov-
Smirnov test. Normally distributed variables were 
described with mean and standard deviation (SD), 
while variables that were not normally distributed 
were described with median, minimum and maxi-
mum. Nominal variables were reported with absolute 
numbers and percentages. To compare characteristics 
of the two groups of patients, we used the parametric 
independent sample t-test for continuous variables and 
its corresponding nonparametric alternative Mantel-
Haenszel or χ2-test for categorical variables. The level 
of significance was set at p<0.05.
Results
Out of 203 patients transplanted at our institution 
during the observed period, 191 were enrolled in the 
study, while 12 patients were lost from follow up. Five 
patients died, four patients underwent graftectomy 
because of life threatening indications (pseudoaneu-
rysm of the renal artery, mycotic aneurysm, pancy-
topenia with fungal infection and graft rejection, and 
retroperitoneal hematoma), one patient rejected the 
graft, and two patients continued follow up at another 
center. 
There were 124 male (64.9%) and 67 female (35.1%) 
patients, mean age 51.04±12.23 years. The main etiol-
ogy of CKD was chronic glomerulonephritis without 
performed biopsy (22.51%), followed by polycystic kid-
ney disease (14.14%) and IgA nephropathy (7.33%). The 
mean time spent on dialysis prior to kidney transplan-
tation was 44.11±29.07 months. The median body mass 
index (BMI) of our patients was 25.97 kg/m2 (min 17.3 
kg/m2, max 43.04 kg/m2). All patients received basilix-
imab induction, tacrolimus, mycophenolate mofetil or 
mycophenolate sodium, and steroids. 
Only 92 of 191 (48.17%) study patients had pa-
rameters of venous blood gas analysis measured at 
some time after kidney transplantation. The mean de-
termined pH value was 7.41 (range, 7.2-7.54). Forty-
one (44.56%) patients were in the state of compen-
sated metabolic acidosis, which means that their pH 
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values were within the reference range but their base 
excess was lower than -2 mmol/L. Three (3.26%) pa-
tients had moderate metabolic acidosis with pH values 
slightly under the reference interval and base excess 
ranging from -6 to -9 mmol/L. Moreover, we found 
that patients with performed pH/blood gas analysis 
had significantly higher creatinine, urea and serum 
calcium (p<0.001) levels, and lower creatinine clear-
ance (p<0.001 all) (Table 1). 
Comparison of BMI between these two patient 
groups yielded no significant difference. The median 
BMI of patients with performed blood gas analysis 
was 25.78 kg/m2 (range, 17.3-43.04 kg/m2), while the 
group without pH determination had median BMI of 
26.06 kg/m2 (range, 19.69-38.28 kg/m2). 
There was no between-group difference in serum 
potassium or sodium level. Episodes of acute rejection 
occurred in 20 patients, without significant difference 
between the groups. 
Discussion
Metabolic acidosis is an important clinical problem 
that needs to be monitored in every kidney transplant 
recipient. Metabolic acidosis may have an impact on 
several metabolic complications, such as bone and 
muscle metabolism, nutritional status, and anemia6,9,10. 
It may also have an effect on graft function5,8,14. 
Results of our study suggested metabolic acidosis 
to be one of the highly underestimated issues among 
nephrologists dealing with transplant recipients. As 
shown by the statistics, only 92 (48.17%) of 191 pa-
tients included in the study had acid-base status de-
termined at some time after kidney transplantation. 
These were mainly patients with much worse kidney 
graft function, which was the leading indication for 
acid-base status analysis. It is also very important to 
mention that 44 patients were found in the state of 
metabolic acidosis. Most of them (44.56%) were in the 
state of compensated acidosis. It is well known that 
mineral and bone metabolism disorders are common 
in patients with CKD15. Serum phosphate level rises 
due to decreased renal phosphate excretion15. Fur-
thermore, the conversion of vitamin D to its active 
form is decreased, leading to decreased serum calcium 
levels and reduced intestinal calcium absorption6,15. 
The disturbed ion balance provokes the synthesis and 
secretion of parathyroid hormone (PTH) in order to 
normalize the disturbed values6,15. 
Metabolic acidosis also contributes to the develop-
ment of chronic kidney bone disease6. The pH of ex-
tracellular fluid is closely protected16. Any increase in 
acidity or alkalinity activates three lines of defense, i.e. 
blood buffers, respiratory system control of CO2, and 
renal excretion of excess acid or base16. Bone is con-
sidered to be an important buffering component6,12. 
Many studies have suggested that decreased pH level 
and low plasma bicarbonate concentration stimulate 
bone resorption and inhibit bone formation6. In vitro 
studies provided evidence that a bone mineral base 
was released into the circulation when administering 
exogenous acid12. If the acidification lasts long enough, 
the bone mineral content and bone mass progressively 
decline and osteoporosis occurs12. Analysis of our data 
showed significantly lower serum calcium levels in the 
group of patients with measured pH/blood gas values. 
Bearing in mind that most of these patients were in 
Table 1. Statistical analysis of groups with acid-base status (ABS) analyzed and not analyzed 
Parameter ABS analyzed ABS not analyzed p value
Creatinine (µmol/L) 196 (87-638) 135 (85-489) <0.001
Creatinine clearance (mL/min) 44.6 (1.3-88.7) 61.7 (12.7-126.7) <0.001
Urea (mmol/L) 11.25 (4.6-40.4) 7.2 (2.9-39.5) <0.001
Calcium (mmol/L) 2.46 (1.9-2.89) 2.53 (2.02-3.04) <0.001
Proteinuria (g/dU) 0.31 (0.04-5.98) 0.37 (0.07-2.88) 0.147
Phosphorus (mmol/L) 1.02 (0.4-2.63) 1.84 (0.5-5.8) 0.348
Potassium (mmol/L) 4.15 (2.8-5.9) 4.28 (3.4-5.5) 0.323
Body mass index (kg/m2) 25.7 (17.3-43.04) 26.19 (19.69-38.28) 0.709
Dialysis vintage (months) 37 (6-133) 46.41 (0-178) 0.256
Data are expressed as mean (range)
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the state of acidosis with slightly reduced graft func-
tion, this could support the hypothesis that metabolic 
acidosis may be a major factor contributing to the de-
velopment of kidney bone disease. 
Malnutrition is a very frequent condition among 
patients with functioning graft17. In their study, 
Chruściel et al. showed that malnutrition could be 
found in more than 20% of transplant recipients17. 
PEW is characterized by a progressive loss of muscle 
and visceral protein stores11. It is very common in pa-
tients with ESRD and can lead to increased debil-
ity and mortality11. The mechanisms responsible for 
muscle protein breakdown are complex and cannot be 
associated only with lower protein intake11. Uremia 
inhibits the regenerative potential of skeletal muscle 
by acting on muscle stem cells11. Several abnormali-
ties such as increased levels of circulating cytokines 
due to the presence of chronic inflammation, oxida-
tive stress and endothelial damage, metabolic acidosis 
and disturbed insulin signaling also stimulate protein 
degradation and inhibit protein synthesis11,18. 
Series of studies suggested that metabolic acidosis 
was one of the most important contributing factors of 
PEW18. Acidosis increases muscle catabolism through 
upregulation of the ATP-dependent ubiquitin-requir-
ing pathway6,18,20. It also reduces protein synthesis, es-
pecially of albumin, and enhances amino acid oxida-
tion, especially degradation of valine6,11,18. Studies in 
rats and humans indicated that the correction of met-
abolic acidosis raised both plasma and muscle protein 
levels by decreasing transamination and decarboxyla-
tion in the muscle6. 
We did not find significant BMI difference between 
the two patient groups. Even when mild, metabolic ac-
idosis may affect graft function. This happens possibly 
through stimulation of adaptive mechanisms aimed at 
maintaining acid-base homeostasis5. Increased am-
monia and endothelin production may cause progres-
sive tubulointerstitial injury and GFR decline, while 
the newly synthesized bicarbonate alkalinizes the in-
terstitium and encourages precipitation of calcium in 
the kidney6,8,10. Finally, studies performed on rats us-
ing the remnant kidney model of CKD indicated that 
the decline in GFR was mediated in part by the ac-
tions of excess aldosterone and endothelin stimulated 
through acid retention10. A limited number of studies 
performed on humans also supported the potential 
role of metabolic acidosis in the progression of CKD6. 
Studies showed that the administration of bicarbon-
ate to individuals with CKD of diverse etiology and 
metabolic acidosis not only slowed the progression of 
CKD (the decline in GFR was less than half of the 
control group who received sodium chloride), but the 
number of individuals developing ESRD was reduced 
significantly6. It is also very important to emphasize 
the impact of immunosuppressive therapy on graft 
function. This specific therapy is one of the corner-
stones of successful kidney transplantation but we of-
ten neglect its negative effects on graft function21,22. 
Chronic allograft nephropathy (CAN) is the lead-
ing cause of graft loss one year after transplantation 
and is associated with a significant rise in morbid-
ity and mortality3,21. Calcineurin inhibitors (CNIs), 
cyclosporine A (CsA) and tacrolimus contribute to 
CAN as strong profibrotic agents22. Most allografts 
show histopathologic signs of CNI toxicity 10 years 
after transplantation3. Initiated fibrogenesis can in 
the end lead to organ failure, thus making it difficult 
to achieve successful long-term allograft outcome22. 
These immunosuppressive agents also contribute to 
the development of metabolic acidosis22,24,25. Accord-
ing to statistical analysis of our data, the assumptions 
about metabolic acidosis affecting graft function may 
be correct. Our analysis showed that patients with 
determined acid-base status indeed had reduced graft 
function. This could be seen from the significantly 
higher median serum levels of creatinine and urea, as 
well as lower median values of creatinine clearance in 
this group of patients. However, this may have been 
the consequence of more frequent ABS evaluation in 
patients with less optimal graft function. Still, many 
patients without determined acid-base status had poor 
graft function. 
In conclusion, the findings in this study indicate 
that metabolic acidosis is still a highly underestimated 
problem among nephrologists dealing with kidney 
transplant recipients. The awareness of acidosis and 
its effects on metabolism and graft function is clearly 
not raised because the majority of our patients with 
satisfactory graft function were found in the state of 
compensated or mild form of acidosis. By evaluat-
ing and correcting these metabolic disturbances, we 
could effectively protect and ameliorate graft function 
and the quality of life of our patients. In our further 
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studies, we plan to determine acid-base status in the 
whole population of kidney transplant recipients from 
our center in order to identify the actual prevalence of 
metabolic acidosis among this specific population.
We suggest regular acid-base status examination 
in renal transplant recipients.
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Sažetak 
METABOLIčKA ACIDOZA – ZANEMARUJEMO LI JE NAKON TRANSPLANTACIJE BUBREGA?
L. Katalinić, K. Blaslov, A. Đanić-Hadžibegović, L. Gellineo, P. Kes, B. Jelaković i N. Bašić-Jukić
Metabolička acidoza je česta komplikacija vezana uz progresivan gubitak bubrežne funkcije. Njezin utjecaj na status 
uhranjenosti, razvoj anemije, koštanu masu i funkciju presađenog bubrega je vrlo složen, ali se može učinkovito spriječiti. 
Istražili smo koliko se određivanju i praćenju acidobaznog statusa (ABS) posvećuje pozornosti u jednom od najvećih tran-
splantacijskih centara unutar organizacije Eurotransplant. U istraživanje su uključeni svi odrasli primatelji bubrega u raz-
doblju od siječnja 2011. do kolovoza 2012. godine. Tijekom promatranog razdoblja transplantirano je 203 bolesnika, a 191 
bolesnik uključen je u istraživanje (124 muškarca i 67 žena, raspona dobi od 18 do 77 godina). Statistička analiza pokazala 
je da je u poslijetransplantacijskom razdoblju ABS bio određen samo u 92 (48,167%) bolesnika. ABS je češće određivan 
muškarcima (p=0,001). Bolesnici s određivanim ABS imali su značajno više vrijednosti kreatinina i ureje (p<0,001), kao i 
značajno niži klirens kreatinina (p<0,001). Ova skupina bolesnika imala je i značajno niže serumske koncentracije kalcija 
(p<0,001). Metabolička acidoza je važno kliničko pitanje koje je potrebno pažljivo razmotriti kod svakog primatelja bubre-
ga. Naše istraživanje pokazalo je da je metabolička acidoza povezana sa značajno višim vrijednostima kreatinina i ureje, 
smanjenim klirensom kreatinina i nižim vrijednostima kalcija. Unatoč tome, metabolička acidoza ostaje uvelike zanema-
ren problem kod ove skupine bolesnika. Preporučamo redovito praćenje acidobaznog statusa svih bolesnika s presađenim 
bubregom.
Ključne riječi: Acidoza; Transplantacija bubrega; Ishod liječenja
